Penumbra Inc
NYSE:PEN

Watchlist Manager
Penumbra Inc Logo
Penumbra Inc
NYSE:PEN
Watchlist
Price: 277.35 USD 2.29% Market Closed
Market Cap: 10.7B USD

During the last 3 months Penumbra Inc insiders have not bought any shares, and sold 2.5m USD worth of shares. The stock price has increased by 15% over this period (open performance analysis).

The last transaction was made on Mar 25, 2025 by Bose Arani (Executive Vice President of Emerging Technologies) , who sold 531.7k USD worth of PEN shares.

Last Transactions:
Bose Arani
Executive Vice President of Emerging Technologies
$-531.7k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-75.9k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-1.6m
Shiu Lambert
$-141.7k
Roberts Johanna
Chief Executive Officer
$-9.1k
O'rourke Bridget
Chief Financial Officer
$-14.3k
Bose Arani
Executive Vice President of Emerging Technologies
$-56.4k
Yuen Maggie
Chief Operating Officer
$-70.8k
Grewal Harpreet
Executive Vice President and President of Asia Pacific
$-40.3k
Kassing Don W.
Lead Independent Director
$-40.6k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-192.6k
Roberts Johanna
Chief Executive Officer
$-8.7k
Shiu Lambert
Chief Financial Officer
$-436.1k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-504.8k
Roberts Johanna
Chief Executive Officer
$-4.2k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-466.6k
Grewal Harpreet
Executive Vice President and President of Asia Pacific
$-31.7k
Roberts Johanna
Chief Executive Officer
$-3.9k
Kassing Don W.
Lead Independent Director
$-33k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-557.1k
Grewal Harpreet
Executive Vice President and President of Asia Pacific
$-159.6k
Roberts Johanna
Chief Executive Officer
$-1.6k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-324k
Roberts Johanna
Chief Executive Officer
$-71.1k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-580.8k
Kassing Don W.
Lead Independent Director
$-30.6k
Roberts Johanna
Chief Executive Officer
$-81.1k
Roberts Johanna
Chief Executive Officer
$-47.3k
Elsesser Adam
Chairman of the Board, President, Co-CEO
$-1.5m
Roberts Johanna
Chief Executive Officer
$-16k
Roberts Johanna
Chief Executive Officer
$-47.6k
Kassing Don W.
Lead Independent Director
$-37.9k
View All Transactions

During the last 3 months Penumbra Inc insiders have not bought any shares, and sold 2.5m USD worth of shares. The stock price has increased by 15% over this period (open performance analysis).

The last transaction was made on Mar 25, 2025 by Bose Arani (Executive Vice President of Emerging Technologies) , who sold 531.7k USD worth of PEN shares.

Sold
0-3
months
2.5m USD
6
3-6
months
1.7m USD
5
6-9
months
1.8m USD
4
9-12
months
1.7m USD
3
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Penumbra Inc
Insider Trading Chart

Penumbra Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Penumbra Inc
Last Insider Transactions

Global
Insiders Monitor

Penumbra Inc
Glance View

Economic Moat
Narrow
Market Cap
10.7B USD
Industry
Health Care

In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.

PEN Intrinsic Value
121.06 USD
Overvaluation 56%
Intrinsic Value
Price

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top